David Euhus
YOU?
Author Swipe
View article: Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection?
Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection? Open
View article: Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database Analysis
Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database Analysis Open
Background: Despite several benefits to neoadjuvant chemotherapy (NAC), there are uncertainties about NAC utilization in early breast cancer. Methods: We performed a retrospective analysis of the National Cancer Database (NCDB), selecting …
View article: Trends, Outcomes, and Costs of Surgical Excisional Biopsy for Fibroadenoma of the Breast
Trends, Outcomes, and Costs of Surgical Excisional Biopsy for Fibroadenoma of the Breast Open
Background De‐escalating the management of fibroadenoma of the breast has been encouraged, but it is not known whether this has been successful. A better understanding of the costs and benefits of surgical excisional biopsy is essential fo…
View article: Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Trebananib vs Control pCR–Biomarker Associations
View article: Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Estimated pCR rates
View article: Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Representativeness of Study Participants
View article: Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Trebananib vs Control pCR–Biomarker Associations
View article: Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
View article: Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Representativeness of Study Participants
View article: Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
View article: Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Purpose:The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast …
View article: Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
View article: Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
View article: Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
View article: Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Estimated pCR rates
View article: Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Purpose:The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast …
View article: Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
View article: Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection?
Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection? Open
View article: Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery Open
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast…
View article: Data from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
Data from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers Open
Improving patient outcome by personalized therapy involves a thorough understanding of an agent's mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the pha…
View article: Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 37K, Detailed RT-PCR results.
View article: Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 37K, Detailed RT-PCR results.
View article: Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate…
View article: Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers Open
PDF file, 1661K, Supplemental Figure S1- Chemical Structures. Supplemental Figure S2-Oxygen Consumption in MCF-7 Cells treated with or without betalapchone and dicoumarol. Supplemental Figure S2 legend. Supplemental Figure S3-Survival assa…
View article: Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 3706K, Pathway Analysis.
View article: Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers Open
PDF file, 1661K, Supplemental Figure S1- Chemical Structures. Supplemental Figure S2-Oxygen Consumption in MCF-7 Cells treated with or without betalapchone and dicoumarol. Supplemental Figure S2 legend. Supplemental Figure S3-Survival assa…
View article: Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate…
View article: Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 19K, Genes modulated by tamoxifen but not placebo in an analysis restricted to premenopausal women.
View article: Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 42K, RT-PCR primer sequences.
View article: Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 42K, RT-PCR primer sequences.